Mammographic Breast Density
Conditions
Brief summary
Increased mammographic density of mammary gland tissues and hyperprolactinaemia are regarded as one of the risk factors for the development of breast cancer in women aged 40 to 52 years, which necessitates closer monitoring of the mammary gland and can be considered as modifiable. The herbal drug Cyclodynone® has a dopaminergic effect on the hypothalamus, which causes its inhibitory effect on the secretion of prolactin. At present, a significant positive clinical and scientific experience has been accumulated in the use of the Cyclodynone® for the treatment of benign breast dysplasias against a background of mild hyperprolactinaemia in women of reproductive age. Demonstration of the positive effect of this drug on the reduction of hyperprolactinemia, mammographic density of MF, evaluation on the scale BI-RADS would justify its application for the modification of this risk factor in women aged 40 to 52 years.
Detailed description
Hypothesis: Increased mammographic density of mammary gland tissues and hyperprolactinaemia are regarded as one of the risk factors for the development of breast cancer in women aged 40 to 52 years, which necessitates closer monitoring of the mammary gland. However, this risk factor can be considered as modifiable. The drug Cyclodynone® (contains 4 mg of special extract of dried fruits of Chaste Berry (Vitex agnus-castus)) has a dopaminergic effect on the hypothalamus, which causes its inhibitory effect on the secretion of prolactin. At present, a significant positive clinical and scientific experience has been accumulated in the use of the Cyclodynone® for the treatment of benign breast dysplasias against a background of mild hyperprolactinaemia in women of reproductive age. However, the experience of using Cyclodynone® in women older than 40-52 years with increased density or dyshormonal pathology of breast cancer is limited. Demonstration of the positive effect of this drug on the reduction of hyperprolactinemia, mammographic density of MF, evaluation on the scale BI-RADS would justify its application for the modification of this risk factor in women aged 40 to 52 years.
Interventions
DRUGCyclodynon
Cyclodynon 1 tablet a day during 6 menthes period.
BEHAVIORALLifestyl modification
Measures to normalize the hygiene of work and rest. A diet aimed at achieving an optimal body mass index. Teaching relaxation techniques to increase resistance to chronic stress.
Sponsors
Bionorica SE
Dr. Struk Tetiana
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Female patients aged 40 to 52 years (inclusive) with mastodynia and BI-RADS category 3, who meet the requirements of inclusion/exclusion criteria will be randomized in 2 groups. The main group will be treated with Cyclodynon 1 tab per day - 6 month in addition to lifestyle modification. The control group lifestyle modification only. Dynamics of mammographic breast density (changing in BI-RADS score of category 3).
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 52 Years
Healthy volunteers
No
Inclusion criteria
* Female patients aged 40 to 52 years (inclusive) with mastodynia and BI-RADS category 3. * The patient's written informed consent to participate in any study-related procedures. * According to the Investigator, the patient's ability to comply with all the requirements of the study protocol, i.e. the patient's ability to cooperate adequately. * Patients who do not have chronic diseases of the cardiovascular system, neuroendocrine system, kidneys, liver, gastrointestinal tract, respiratory system, skin in the decompensation stage. * Consent to use reliable, evidence-based contraceptive methods (double containing the following types: hormonal, barrier, intrauterine spiral, etc.) throughout the study (from the time of the Informed Consent to Visit 6) .
Exclusion criteria
* Hypersensitivity to the components of the IMP. * Burdened history of allergies. * Participation in another clinical study less than 90 days before signing the informed consent form. * History of cancer. * Pregnancy or lactation. * Administration of dopamine agonists, dopamine antagonists, oestrogens and antiestrogens, dopamine. * Secondary amenorrhoea within 6 months or more. * Surgical, pharmacological or physiological menopause (except hysterectomy). * The prolactin level is more than 80 ng/mL. * Other reasons which make the patient's participation in the study undesirable, according to the Investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mammographic density | 6 month | Decrease in the mammographic density determined by a mammographic breast examination at Visit 5 compared to baseline (Visit 1). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| BI-RADS indicator | 6 month | Dynamics of BI-RADS indicator determined by a mammographic breast examination. |
Countries
Ukraine
Contacts
Primary ContactTetiana Struk, Ph.D.
Backup ContactPopov Alexet, Ph.D
Outcome results
None listed